People · Operator
Named in public records as an officer, director or promoter · active 2022–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sunshine Biopharma, Inc | — | Pharmaceuticals | Series B | $33.0M | $54.9M | 2022 |
Andrew N. Keller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew N. Keller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steve N. Slilaty | 1 | 1 |
| Camille N. Sebaaly | 1 | 1 |
| Michele N. Di Turi | 1 | 1 |
| Rabi N. Kiderach | 1 | 1 |
| Abderrazzak N. Merzouki | 1 | 1 |
| David N. Natan | 1 | 1 |
| Rabi N. Kiderchah | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.